On July 6, TransThera Sciences-B rose 6.19% in regular trading, trading at HK$12.56/share, with turnover of HK$136 million. The stock was lifted by a broad biotech sector rally alongside company-specific catalysts including recent clinical milestones and a share buyback plan.

On July 1, the company announced that its global registrational Phase III clinical trial of tinengotinib monotherapy for advanced cholangiocarcinoma completed patient enrollment. The same day, its TT-01488 Phase II clinical trial combining anti-CD20 monoclonal antibody therapy for mantle cell lymphoma received approval from China's NMPA. Additionally, on June 28, the board announced a plan to repurchase up to RMB 100 million of H shares on the open market, bolstering market confidence.

At the sector level, biotech stocks rallied broadly, with Innovent Bio up 7.4%, Remegen up 6.26%, and SKB Bio up 6.41%, reflecting strong industry sentiment that further supported the stock's rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)